TABLE 2.
Main demographic data, clinical characteristics, laboratory, and imaging results in described MOG-Ab associated cerebral cortical encephalitis.
| Population characteristics | |
| Mean age, years | 25 (Range 4–52) |
| Median age, years | 24 |
| Sex | 19M/16F (M: F = 19:16) |
| Clinical presentation | |
| Seizures | 28/35 (80.0%) |
| Headache | 26/35 (74.3%) |
| Fever | 17/35 (48.6%) |
| Paralysis | 11/35 (31.4%) |
| Psychiatric symptoms | 10/35 (28.6%) |
| Language disorder | 9/35 (25.7%) |
| Antibody test (CBA) | |
| Serum Mog-IgG | 35/35 (100%) |
| Mog-IgG titer | 1:10–1:2560 |
| EEG patterns | |
| Slow wave | 8/18 (44.4%) |
| Epileptiform wave | 5/18 (27.8%) |
| Normal | 3/18 (16.7%) |
| Neuroimaging | |
| FLAIR hyperintensity | 31/35 (88.6%) |
| Unilateral cortical involvement | 30/35 (85.7%) |
| Bilateral cortical involvement | 5/35 (14.3%) |
| Cortical involvement site | |
| Parietal lobe | 24/35 (68.6%) |
| Frontal lobe | 24/35 (68.6%) |
| Temporal lobe | 15/35 (42.9%) |
| Occipital lobe | 6/35 (17.1%) |
| Intervention | |
| HIMP | 30/35 (85.7%) |
| IVIg | 5/35 (14.3%) |
| Immunosuppressant | 9/35 (25.7%) |
| Relapse | 2/35 (5.7%) |
| Outcome | |
| Fully recovery | 25/35 (71.4%) |
| Partial recovery | 9/35 (25.7%) |
| Death | 1/35 (2.9%) |
M, male; F, female; CBA, cell-based assay; MOG, myelin oligodendrocyte glycoprotein; EEG, electroencephalogram; FLAIR, fluid-attenuated inversion recovery; HIMP, high-dose intravenous methylprednisolone; IVIg, intravenous immunoglobulin.